Submit your Center of Excellence Application today!

Read More


Oct 13, 2019

In-office gene therapy for wet age-related macular degeneration is coming

by American Academy of Ophthalmology

Gene therapy is showing promise for one of the most common causes of blindness. Data presented today shows that six patients with wet age-related macular degeneration (AMD) have, so far, gone at least six months without the need for continued injections to control a disease that typically requires treatment every four to six weeks. Researchers say the hope is that gene therapy will free patients from nearly monthly eye injections by offering a potential “one-and-done” treatment. It’s not just about convenience; a more consistent treatment may also help people keep more of their vision. The research will be presented today at AAO 2019, the 123rd Annual Meeting of the American Academy of Ophthalmology.

“This is potentially paradigm shifting,” said lead researcher, Szilárd Kiss, M.D., director of Clinical Research and chief of the Retina Service in the Department of Ophthalmology at Weill Cornell Medical College in New York City. “It’s the next revolutionary leap in treating AMD. When you think about what is science fiction and what is science reality; gene therapy for AMD is becoming a clinical reality.”

Dr. Kiss expects a gene therapy for wet AMD could be available within the next three to five years, depending upon the results of further clinical studies and regulatory approvals……

Read more:

Source: Medical Express

Leave a Reply

Your email address will not be published. Required fields are marked *

Newsletter Sign-up

  • This field is for validation purposes and should be left unchanged.